Quark Venture

Portfolio · 6

EyeYon Medical

Ophthalmic Products for Vision-threatening Conditions

1 round $25.0M committed Latest: 2021-03

Variantyx

Advanced Genomic Diagnostic Solutions

Led ★ 1 round $26.0M committed Latest: 2021-03

V-Wave

Miniature Shunt for Treating Congestive Heart Failure

1 round $98.0M committed Latest: 2020-09

Raziel Therapeutics

Injectable Drug for Treatment of Obesity

1 round $22.0M committed Latest: 2019-12

Pi Therapeutics

Inhibitors for Cancer Treatment

1 round $19.7M committed Latest: 2019-05

CathWorks

Noninvasive FFR Measurements for Coronary Interventions

1 round $15.8M committed Latest: 2017-10

Investment activity

2 portfolio exits on record.

Q&A

What is Quark Venture's primary investment focus?

Quark Venture primarily focuses on investments within the Health Tech & Life Sciences sector, with all six of its portfolio companies operating in this area.

Can you name some of Quark Venture's notable exits?

Quark Venture has seen two notable exits: CathWorks was acquired by Medtronic for $585M in February 2026, and V-Wave was acquired by Johnson & Johnson for $600M in August 2024.

Which portfolio companies has Quark Venture invested in?

Quark Venture's portfolio includes companies such as CathWorks, which develops noninvasive FFR measurements, and EyeYon Medical, focused on ophthalmic products.

What is the typical funding stage for Quark Venture's investments?

Quark Venture frequently invests in later-stage rounds, with two investments in Series B rounds and four in Series C rounds.

When did Quark Venture make its most recent investments?

Quark Venture made two investments in March 2021, following one in September 2020.

What is the investment range for Quark Venture?

Quark Venture's investment range is between $15.8M and $98M.